Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1 × pertuzumab × Gynecologic × Clear all

Phase

Phase 2 3 Phase 3 2 Phase EARLY_PHASE1 1 Phase 2/3 1 Phase 1/2 1 Phase 1 1

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 16 Other solid neoplasm 3 Tumor-Agnostic 1 Thoracic 1 Plasma cell 1 Other hematologic neoplasm 1 Myeloid 1 Lymphoid 1 Gynecologic 1 Genitourinary 1 Gastrointestinal 1 Classical hematology 1 CNS 1

Conditions

Endometrial Neoplasms 1 Breast Neoplasms 1

Interventions

Paclitaxel 99 Carboplatin 87 Cisplatin 61 pembrolizumab 58 Cyclophosphamide 41 Bevacizumab 33 Taxes 28 liposomal doxorubicin 26 Gemcitabine 26 fludarabine 22 Topotecan 22 Docetaxel 19 Radiotherapy 18 Nivolumab 18 olaparib 17 Brachytherapy 17 veliparib 15 Magnetic Resonance Spectroscopy 15 Biopsy 15 Radiation 14 Platinum 13 Doxorubicin 13 niraparib 12 Specimen Handling 12 Oxaliplatin 12 Filgrastim 12 aldesleukin 11 1,2-diaminocyclohexaneplatinum II citrate 11 sargramostim 10 Interleukin-2 10

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04188548 2025-06-04

EMBER

Eli Lilly and Company

Phase 1 Active not recruiting

BreastGynecologic

Breast Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡